Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US).
The new 20-acre site will extend the firm’s ability to manufacture various CAR-T therapies including Kite’s cancer treatment Yescarta.
Tim Moore, Executive VP of Technical Operations at Kite, explained: “This new facility in Frederick County builds on our substantial technical capabilities and rapid progress in making personalised CAR-T and TCR cell therapies for people with cancer.”